In late October thousands of infectious-disease clinicians converged on Washington, DC, for IDWeek 2026, and disAMR was there to cover it. Over the course of several days, what emerged was a jarring picture of a worsening and costly pandemic, and simultaneously, a hopeful picture with a host of promising early-stage solutions. Below are some takeaways from the conference and key openings for action.
Winning the Drug-Microbe Arms Race is Tougher Than Ever
Despite rapid diagnosis and treatment, a nine-year-old boy died of a bacterial infection that resisted multiple drugs. Lab investigation revealed that the culprit was one of the toughest superbugs—a strain of E. coli with a drug-inactivating enzyme called New Delhi metallo-beta-lactamase (NDM-1). It also revealed a scientific path that could let doctors stay one step ahead of NDM-containing bacteria. Read more here.1
Tailor Stewardship Plans to Local Conditions
In sub-Saharan Africa, clinicians and health workers face challenges many of their counterparts in the Global North rarely do, including easy public access to antibiotics, clinicians with little AMR training, paper-based hospital records, and slow diagnosis of fast-moving infections. A program from React Africa has begun to overcome these hurdles with digital tools for clinicians, education, cultural understanding and community involvement. The effort offers a new model for effective antibiotic stewardship in LMICs. Read more here.2
Investments Fighting AMR are Bound to Pay Off
An economic analysis presented at IDWeek revealed societal costs of AMR of $1 trillion a year—far larger than previous estimates. Unlike previous studies, which tallied only the cost of clinical care, this one looked at the cost of AMR in good health and productivity. Another economic study presented at the conference forecast skyrocketing costs for US hospitals alone—costs that dwarf the $6 billion in pull incentives that the proposed Pasteur Act would bring. Numbers like these make it clear that effective investments against AMR will benefit society. Read more here.3
Connect AMR Innovators
Drug development, diagnostics, stewardship, surveillance, economics, and implementation too often remain distinct conversations. But advances in one area are often constrained by limitations in another. Future progress depends on convening stakeholders across disciplines, addressing the gaps, and defining integrated solutions. Read more here.4
Make Implementation Part of Innovation
Demonstrating in a pilot test that an intervention works is not the same as proving that it will reach and benefit patients. Not all interventions can be adopted, sustained, and reproduced elsewhere, and what works in one setting may not deliver meaningful impact in another. Implementation science, the scientific study of methods to incorporate evidence-based innovations and practices into routine medical care, can help. . A stronger focus on implementation evidence can improve delivery of promising advances into routine practice. Read more here.4
AMR Innovations are Waiting in the Wings
From penicillin to the present, small-molecule antibiotics have been a clinical mainstay for fighting infections, but dozens of newer strategies are being tested, according to several speakers at IDWeek 2026. Antimicrobial peptides and CRISPR-Cas-based therapeutics are among them, said Robert A. Bonomo, an infectious disease physician at Case Western Reserve University and the Cleveland VA Medical Center. So are drugs that block antibiotic efflux pumps, disarm pathogens without killing them, and targeted bacteriophage therapies.
Alternatively, Bonomo said, the evolution of bacterial resistance could be steered to prevent resistance by altering the order in which antibiotics are given to the patient, or slowed using inhibitors of mutagenesis. New vaccines can help by triggering broad immunity that pathogens find hard to evade.5,6
Other innovations enlist friendly microbes to fight off foes, said Christopher Lehman, a professor of pediatric infectious disease at the University of Chicago Pritzker School of Medicine. A healthy gut microbiome contains trillions of bacteria that outcompete antibiotic-resistant pathogens by grabbing nutrients they need, or by releasing microbe-targeting toxins to kill them.4 Alternatively, clinicians can seed patients with a healthy microbiome to restore it.
Evidence-based psychosocial approaches could also reduce AMR, Bonomo said, including public education, prescriber feedback and health psychology frameworks to modify prescribing habits.
With these tools and others and a strategic approach, Bonomo said, scientists would not have to scramble to continue developing new drug combinations to treat new types of antimicrobial resistance. Instead, we’d predict resistance and avert the threat.
